The interest in terbium radionuclides, which can be used in nuclear medicine, has increased tremendously over the last decade. Several research studies have shown the potential of four terbium radionuclides Tb both for cancer diagnosis as well as therapy. The comparison of Tb and Lu showed Tb as the preferred candidate not only for standard radiotherapy, but also for the treatment of minimal residual disease. Nevertheless, among the terbium sisters, currently, only Tb has an established production protocol where its no-carrier-added form is obtained via neutron irradiation of enriched Gd targets. The other terbium radioisotopes face challenges related to production capacity and production yield, which currently restricts their use in nuclear medicine. The purpose of this review is to report on recent research on the production and separation of terbium sisters and to assess the prospects for upscaling their production for nuclear medicine applications.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11502363 | PMC |
| http://dx.doi.org/10.3389/fnume.2024.1472500 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Terbium sisters: current development status and upscaling opportunities.
Front Nucl Med
October 2024
Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen PSI, Switzerland.
The interest in terbium radionuclides, which can be used in nuclear medicine, has increased tremendously over the last decade. Several research studies have shown the potential of four terbium radionuclides Tb both for cancer diagnosis as well as therapy. The comparison of Tb and Lu showed Tb as the preferred candidate not only for standard radiotherapy, but also for the treatment of minimal residual disease.
View Article and Find Full Text PDFSimple triple-label detection of seven cystic fibrosis mutations by time-resolved fluorometry.
Clin Chem
July 1997
Department of Biotechnology, University of Turku, Finland.
We describe a simple hybridization assay performed in microtitration wells with use of DNA probes labeled with three different lanthanide chelates for detection of seven mutations that cause cystic fibrosis. The assay is based on DNA amplification of four fragments containing the mutations (delta F508, G1717-->A, G542X, R553X, 3905 insertion T, W1282X, and N1303K) by PCR, followed by hybridization with short, allele-specific oligonucleotide probes labeled with europium, terbium, or samarium chelates. Because the technology makes it possible to hybridize three DNA probes simultaneously in one reaction, all 14 mutation-related alleles were detected in a total of five reaction wells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!